Reports Of Gilead's Death Are Greatly Exaggerated

Reports Of Gilead's Death Are Greatly Exaggerated


Gilead's revenues were mostly driven by its HCV-segment which is currently in free fall given that the company sort of eroded its customer base. Gilead's valuation is low but dividend hikes and surging non-HCV revenues provide promising return catalysts for long-term investors.



from Biotech News